Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. It is developed and produced by the Dutch biotechnology company Micreos.[1][2] It became the first commercially available endolysin and is marketed in Gladskin products.[3]
The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.[4] The enzyme has successfully been used for treatment of S. aureus-related dermatosis.[5]
References
edit- ^ Parmley S (2014-12-11). "Lysin in wait". SciBX: Science-Business EXchange. 7 (47): 1369. doi:10.1038/scibx.2014.1369.
- ^ Herpers BL, Leeson N (2015-03-01). "Endolysins: redefining antibacterial therapy". Future Microbiology. 10 (3): 309–11. doi:10.2217/fmb.14.142. PMID 25812452. S2CID 45404710.
- ^ "Technology". Gladskin EU. Retrieved 2020-01-10.
- ^ Siew A (Apr 21, 2015). "Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability" – via www.pharmtech.com.
- ^ Totté JE, van Doorn MB, Pasmans SG (2017-05-22). "Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases". Case Reports in Dermatology. 9 (2): 19–25. doi:10.1159/000473872. PMC 5465516. PMID 28611631.
External links
edit
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |